Patients undergoing major orthopedic surgery, including total hip arthroplasty (THA) and total knee arthroplasty (TKA), are at high risk for developing venous thromboembolism (VTE). Although largely a preventable complication, VTE develops in a significant proportion of patients, highlighting the need for improved methods of VTE prevention. Current thromboprophylactic options are limited by unpredictable pharmacokinetics and pharmacodynamics (vitamin K antagonists), parenteral/subcutaneous administration (heparin and low-molecular-weight heparins), complicated dosing, and increased risk of bleeding.
Editor's CommEnt
The Editor would like to issue a word of caution on rivaroxaban use, especially in surgical settings where bleeding issues exist and in situations that may require the need for sudden reversal. Bleeding issues were experienced with dextran in the 1960s. Reversal techniques currently exist with heparin and coumadin, and not having the ability to reverse treatment, especially in the trauma and surgical settings, is a limitation of rivaroxaban. I have not changed my prophylaxis regimen since the approval of rivaroxaban.
Robert D. D'Ambrosia, MD
Editor-in-Chief, OrthOpedics P atients undergoing major orthopedic surgery, including total hip arthroplasty (THA) and total knee arthroplasty (TKA), are at high risk for developing venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism. Prophylaxis with anticoagulants after THA or TKA is recommended for 2 weeks to reduce the risk of VTE and subsequent morbidity and mortality, which often occur after patients have been discharged. Guidelines recommend extending thromboprophylaxis to 35 days after THA. 1 Thromboprophylactic options include vitamin K antagonists (eg, warfarin), heparin, low-molecular-weight heparins (LMWHs) such as enoxaparin, the synthetic pentasaccharide fondaparinux (an indirect Factor Xa inhibitor), and acetylsalicylic acid. However, acetylsalicylic acid is an antiplatelet agent rather than an anticoagulant, and the American College of Chest Physicians (ACCP) guidelines specifically recommend against the use of acetylsalicylic acid alone as a thromboprophylactic strategy for the prevention of VTE. 2 Recent studies have highlighted the poor uptake of guideline-recommended thromboprophylaxis after major orthopedic surgery, with approximately half of patients receiving care as recommended in the seventh ACCP guidelines in the United States and across other global health care systems.
3,4 Low compliance with guideline recommendations may be a result of the limitations of current thromboprophylactic agents. These limitations include unpredictable pharmacokinetics and pharmacodynamics (vitamin K antagonists), parenteral/subcutaneous administration (heparin, fondaparinux, and LMWHs), complicated dosing, and the poor balance between efficacy and bleeding. As such, an ongoing need exists for additional prophylactic options that will ideally offer an oral route of intake, once-daily administration, and fixed dosing over a wide range of patients. Such features could potentially improve patient compliance.
Rivaroxaban is an oral, direct Factor Xa inhibitor that was approved by the Food and Drug Administration in July 2011 for the prophylaxis of DVT, which may lead to pulmonary embolism, in patients undergoing hip or knee replacement. The pharmacologic and clinical properties of this agent may address the limitations of older thromboprophylactic options. This article provides an overview of the rationale for once-daily dosing with rivaroxaban in this indication and reviews the phase III results of rivaroxaban for the prevention of VTE after THA or TKA.
CliniCal PharmaCology of rivaroxaban
The clinical pharmacology of rivaroxaban in healthy men has been assessed in 2 phase I studies. Rivaroxaban demonstrated a good safety profile when administered to healthy volunteers over the dose range of 5 to 60 mg/day, with no clinically relevant changes in bleeding time or other safety variables across all doses and regimens evaluated. 5 Rivaroxaban dose-dependently inhibits Factor Xa, with the maximum inhibitory effect occurring 1 to 4 hours after administration, with detectable thrombin inhibition persisting at 24 hours for doses .5 mg. 5, 6 This latter observation suggested that once-daily dosing might be feasible. A multiple-dose study also showed that maximum inhibition did not differ significantly between initial drug administration and steady state, indicating no substantial accumulation of rivaroxaban after multiple doses. 5 Rivaroxaban also dose-dependently prolonged the prothrombin time, again with no apparent accumulation of effect. [5] [6] [7] These studies also provided important information on the pharmacokinetic profile of rivaroxaban (Table 1) . Rivaroxaban displayed dose-proportional pharmacokinetics (over the range of 5 to 60 mg/day) that correlated closely with the pharmacodynamic profile described previously. 5 To determine whether dose adjustment might be necessary for defined patient populations, the pharmacokinetic profile of rivaroxaban was also determined by age group, sex, and body weight. 8, 9 Age had no significant effect on the maximum plasma concentration (C max ) achieved with rivaroxaban, although bioavailability was higher in elderly participants compared with younger participants. 10 Similarly, regarding the inhibition of Factor Xa activity and the prolongation of prothrombin time, the area under the concentration-time curve was higher in elderly participants than in younger participants. 10 However, the maximum effect for these parameters was not affected significantly by age. 10 Neither sex nor body weight were found to appreciably affect the pharmacokinetic or pharmacodynamic profile of rivaroxaban. 9, 10 Thus, dose adjustment of rivaroxaban was considered to be unnecessary in these patient populations.
9,10
The effects of renal or hepatic impairment on the pharmacology of rivaroxaban have also been evaluated. 11, 12 Increasing renal impairment resulted in decreased renal clearance, and hence decreased total body clearance of rivaroxaban, resulting Circulating metabolites None in increased overall exposure to rivaroxaban. 11 This was reflected in the higher area under the concentration-time curve values in participants with mild, moderate, and severe renal impairment (44%, 52%, and 64% higher, respectively) compared with healthy participants (P,.05). 11 However, the C max of rivaroxaban was relatively unaffected, confirming that the increased exposure to rivaroxaban was a result of decreased clearance rather than increased absorption. Patients with mild or moderate renal impairment were included in phase II clinical studies and received the same fixed dose as those without renal impairment, with no apparent effects on efficacy or safety. In a separate study, in participants with mild hepatic impairment, rivaroxaban showed no clinically relevant pharmacologic differences compared with healthy participants. However, in participants with moderate hepatic impairment, a decrease in rivaroxaban clearance was observed, which led to increased plasma levels, an increase in Factor Xa inhibition activity, and prolongation of prothrombin time. 12 Rivaroxaban has not been studied in patients with significant hepatic disease associated with coagulopathy leading to a clinically relevant bleeding risk.
Rivaroxaban has a low risk of drugdrug interactions with frequently used concomitant medications. Randomized studies in healthy participants have investigated the effect of concomitant medications on the safety, tolerability, pharmacokinetics, and pharmacodynamics of rivaroxaban. When coadministered with acetylsalicylic acid, naproxen (a nonsteroidal antiinflammatory drug [NSAID]), enoxaparin, digoxin, atorvastatin, H 2 antagonists, or antacids, no clinically relevant effect on the pharmacodynamic profile of rivaroxaban was observed. [13] [14] [15] [16] [17] [18] [19] Rivaroxaban is not recommended in patients concomitantly receiving strong inhibitors of cytochrome P450 3A4 (CYP3A4) or the transport protein P-glycoprotein (P-gp)-both of which are involved in the elimination of rivaroxaban-because these may increase rivaroxaban plasma concentrations to a clinically relevant degree, which may increase the risk of bleeding. These agents include azole-antimycotics (such as ketoconazole, itraconazole, voriconazole, and posaconazole) and human immunodeficiency virus protease inhibitors (such as ritonavir). 20 No specific antidote exists to reverse the effects of rivaroxaban; however, preclinical studies suggest that the administration of recombinant activated Factor VII or activated prothrombin complex concentrate may reverse the effects of high-dose rivaroxaban. [21] [22] [23] A study in healthy participants also showed that prothrombin complex concentrate reversed the anticoagulant effect of rivaroxaban. 24 If standard strategies such as delaying the next dose of rivaroxaban or discontinuation, mechanical compression, surgical intervention, and blood product transfusion fail to control bleeding, these agents may be considered as antidotes in bleeding emergencies. However, there is currently little experience with the use of either of these agents in patients receiving rivaroxaban.
CliniCal studiEs: PrEvEntion of vEnous thromboEmbolism

Phase II: ODIXa Studies
Rivaroxaban was assessed relative to the LMWH comparator enoxaparin for the prevention of VTE after THA or TKA in 4 phase II studies. [25] [26] [27] [28] A large and extensive phase II program assessed once-daily and twice-daily dosing regimens, over a twelvefold dose range of rivaroxaban (total daily doses, 5-60 mg). [25] [26] [27] [28] Details of the study designs and of the efficacy and safety endpoints are summarized in Table 2 .
These dose-finding studies indicated that all tested rivaroxaban dose regimens had similar efficacy to enoxaparin. The open-label ODIXa (Oral, DIrect Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement)-HIP study 25 demonstrated the proof of principle of rivaroxaban for the prevention of VTE after THA. Results with the rivaroxaban 30 mg once-daily dose for efficacy and safety were similar to the twice-daily results, indicating that once-daily dosing of rivaroxaban was feasible. The ODIXa-HIP2 and ODIXa-KNEE studies demonstrated that rivaroxaban regimens of 5 to 20 mg total daily dose offered a flat dose-response relationship after THA and TKA for the composite primary efficacy endpoint of DVT, pulmonary embolism, and all-cause mortality 26, 27 and were considered to provide the most favorable balance between efficacy and safety. The data from these studies highlighted the wide therapeutic window for rivaroxaban. These studies also confirmed that the incidence of major bleeding over this dose range was similar to that of enoxaparin. Finally, a once-daily dosing study, ODIXa-HIP-OD, 28 in association with the results of other studies, indicated that the optimum dose of rivaroxaban when efficacy and safety outcomes were considered together was 10 mg once daily.
The pharmacodynamic relationship between rivaroxaban plasma concentration and prothrombin time is similar in healthy participants and in patients undergoing THA or TKA. 29 A pooled analysis of 2 phase II studies of rivaroxaban given either once or twice daily in patients undergoing THA 26, 28 suggested that differences in plasma concentrations between the 2 regimens were not clinically relevant. 30 The analysis also confirmed the predictable pharmacokinetic/pharmacodynamic profile of rivaroxaban in patients, which was consistent with that observed in healthy participants. 30 These data support fixed dosing of rivaroxaban regardless of age, sex, or body weight, and in patients with mild-to-moderate renal impairment. 30 In addition, evaluation of rivaroxaban plasma concentrations in extreme case scenarios-patients with extremes of the demographic factors-suggested these factors should not lead to significant changes in rivaroxaban exposure after a 10 mg once-daily dose (Figure 1 ). 30 These data further supported a fixed dose of rivaroxaban 10 mg once daily for a wide range of patients.
Phase III Studies: The RECORD Program
The RECORD (REgulation of Coagulation in ORthopaedic surgery to prevent Deep vein thrombosis and pulmonary embolism) program comprised 4 studies investigating the efficacy and safety of rivaroxaban 10 mg once daily compared with standard doses of enoxaparin in .12,500 patients undergoing THA or TKA (Table 3) . [31] [32] [33] [34] All patients in the RECORD studies received once-daily rivaroxaban. There was no upper age or weight limit for participation. The primary efficacy endpoint of these studies was the composite of DVT, nonfatal pulmonary embolism, and all-cause mortality (total VTE) up to day 42 in the hip studies and up to day 17 in the knee studies. Major and symptomatic VTE were also evaluated. The primary safety endpoint was major bleeding. The RECORD1 study, in patients undergoing THA, showed that rivaroxaban was significantly more effective than enoxaparin 40 mg once daily for extended prophylaxis in patients undergoing THA. 31 Total VTE and major VTE occurred at a significantly lower frequency than with enoxaparin, whereas symptomatic VTE occurred in fewer patients, but the difference did not reach statistical significance (Table 4) .
The results of the RECORD2 study in patients undergoing THA demonstrated that extended-duration rivaroxaban prophylaxis was significantly more effective than short-duration prophylaxis with enoxaparin followed by placebo in patients undergoing THA. 32 Total VTE, major VTE, and symptomatic VTE occurred at a significantly lower frequency with rivaroxaban than with (Table 4) . This supports the benefits of the recommended duration of therapy after THA (35 days). In RECORD3, in patients undergoing TKA, rivaroxaban was significantly more effective than enoxaparin 40 mg once daily for short-term prophylaxis in patients undergoing TKA, with a similar safety profile. 33 Total VTE, major VTE, and symptomatic VTE were significantly less frequent with rivaroxaban than with enoxaparin (Table 4) .
The RECORD4 study, in patients undergoing TKA, showed rivaroxaban to be significantly more effective than the standard US regimen of enoxaparin 30 mg twice daily every 12 hours. 34 This is the only study to date of a new oral anticoagulant that has shown superiority to this regimen after TKA. Apixaban and dabigatran (direct inhibitors of Factor Xa and thrombin, respectively) failed to show noninferiority to enoxaparin 30 mg twice daily after TKA. 35, 36 The safety profile for rivaroxaban was consistent with that previously reported across the phase II studies. The incidence of major bleeding across the RECORD studies was similar to that for enoxaparin (Table 4 ). The incidence of cardiovascular events during treatment was low and similar between rivaroxaban and enoxaparin, and no consistent treatment differences were observed after completion of drug administration. No additional safety concerns were raised for rivaroxaban therapy across the 4 phase III clinical trials conducted for this agent. No evidence was found of any liver safety issues attributable to rivaroxaban.
ConClusion
Rivaroxaban has been shown to be an effective oral anticoagulant. In healthy participants, it has a rapid onset of action and predictable regulation of coagulation after a single dose and multiple dosing. A low risk of drug-drug interactions exists with frequently used medications such as acetylsalicylic acid and NSAIDs. Rivaroxaban has shown effective anticoagulation and a favorable safety profile in clinical studies for the prevention of VTE after THA or TKA.
The clinical pharmacology of oral rivaroxaban, in combination with results from phase II studies, suggested that once-daily, fixed dosing was feasible for the prevention of VTE after THA or TKA, without compromising efficacy and safety. These findings have been confirmed in large phase III VTE prevention studies where rivaroxaban 10 mg once daily after THA or TKA was shown to have superior efficacy in the prevention of VTE with a similar incidence of major bleeding compared with enoxaparin regimens. Across the RECORD studies, no evidence was found of a requirement for routine coagulation monitoring or dose adjustment. In all 4 studies, rivaroxaban demonstrated superior efficacy without compromising safety. Rivaroxaban was significantly more effective than enoxaparin regimens in the prevention of total VTE (Figure 2 ). Rivaroxaban represents an effective, well-tolerated, and convenient alternative to the other anticoagulants licensed for VTE prevention after major orthopedic surgery. Because it is administered orally, once daily, and at a fixed dose without the need for routine coagulation monitoring, rivaroxaban is a convenient and effective option for patients and physicians after THA or TKA. Figure 2: Summary of the incidence of total venous thromboembolism from the RECORD trials. [31] [32] [33] [34] RECORD2 compared extended prophylaxis with rivaroxaban (3564 days) with short-term prophylaxis with enoxaparin (1262 days).
